55,121 Shares in Olema Pharmaceuticals, Inc. $OLMA Acquired by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC purchased a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) in the second quarter, Holdings Channel.com reports. The institutional investor purchased 55,121 shares of the company’s stock, valued at approximately $690,000.

Several other hedge funds also recently added to or reduced their stakes in OLMA. Bain Capital Life Sciences Investors LLC boosted its stake in Olema Pharmaceuticals by 24.3% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock valued at $212,716,000 after acquiring an additional 1,664,687 shares in the last quarter. Paradigm Biocapital Advisors LP boosted its holdings in shares of Olema Pharmaceuticals by 11.0% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,544,172 shares of the company’s stock valued at $188,604,000 after acquiring an additional 750,000 shares during the period. Janus Henderson Group PLC grew its position in shares of Olema Pharmaceuticals by 5.9% during the first quarter. Janus Henderson Group PLC now owns 7,108,488 shares of the company’s stock worth $106,013,000 after acquiring an additional 398,294 shares during the last quarter. Jupiter Topco LLC acquired a new position in shares of Olema Pharmaceuticals in the 2nd quarter valued at $88,803,000. Finally, BlackRock Inc. acquired a new stake in Olema Pharmaceuticals during the 2nd quarter worth $84,001,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Olema Pharmaceuticals Stock Performance

NASDAQ OLMA opened at $10.83 on Thursday. The company has a current ratio of 8.86, a quick ratio of 8.86 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $11.45 and its two-hundred day moving average is $14.02. Olema Pharmaceuticals, Inc. has a 12-month low of $5.99 and a 12-month high of $36.26. The stock has a market capitalization of $947.62 million, a price-to-earnings ratio of -5.11 and a beta of 1.98.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.06). Research analysts expect that Olema Pharmaceuticals, Inc. will post -2.43 EPS for the current year.

Wall Street Analyst Weigh In

OLMA has been the topic of a number of recent research reports. Citigroup dropped their price objective on shares of Olema Pharmaceuticals to $59.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. Guggenheim decreased their target price on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Weiss Ratings lowered Olema Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. HC Wainwright lowered their price target on Olema Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. Finally, Wall Street Zen cut Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 25th. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $42.40.

Insider Transactions at Olema Pharmaceuticals

In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 12,500 shares of the stock in a transaction on Thursday, July 23rd. The stock was sold at an average price of $11.58, for a total value of $144,750.00. Following the completion of the transaction, the director owned 715,270 shares in the company, valued at approximately $8,282,826.60. This represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 12.56% of the company’s stock.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.